June 23rd 2025
Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
View More
GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
View More
From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment
View More
Proactive Adverse Event Management for HER2+ BTC Treatments
View More
COMING SOON: Around the Practice: ctDNA Analysis to Direct Treatment Decisions in Colorectal Cancer
June 28th 2023Tanios S. Bekaii-Saab, MD, provides a look at an upcoming Cancer Network Around the Practice program in which a panel of experts will present the case of a patient with colorectal cancer, review updates from clinical trials, and provide insights on the role of ctDNA in treatment decision-making.
FDA Approves FoundationOne LiquidCDx for Encorafenib Combo in mCRC
June 12th 2023The FDA’s approval of the FoundationOne Liquid CDx as a companion diagnostic may improve access to treatment with encorafenib plus cetuximab for patients with metastatic colorectal cancer harboring a BRAF V600E alteration.
Preoperative FOLFOX Appears Noninferior Vs CRT in Rectal Cancer
June 4th 2023“We think that we can successfully de-escalate treatment of rectal cancer and achieve the same high cure rates [and] keep patients disease free, with less long-term toxicity and effects,” lead author Deb Schrag, MD, FASCO, MPH, said.
Tucatinib/Trastuzumab Yields Durable Responses in HER2+ Metastatic CRC
June 2nd 2023Tucatinib plus trastuzumab represents a valuable, novel option for HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer that is chemotherapy refractory, according to the authors of the phase 2 MOUNTAINEER trial.
Colorectal Cancer: Insights on ctDNA and Retesting for HER2 Expression
A panel of experts discuss the role of ctDNA and their practices for retesting HER2 expression to guide treatment for colorectal cancer.
Patient Profile: A 40-Year-Old Woman With Colorectal Cancer
Experts on colorectal cancer present the case of a 40-year-old woman with CRC, who receives later-line treatment with trastuzumab deruxtecan, and share their initial thoughts.
Patient Profile: A 47-Year-Old Woman With HER2+ CRC and Early Disease Progression
Expert oncologists present the case of a 47-year-old woman with colorectal cancer and early disease progression, and discuss treatment options with the ongoing MOUNTAINEER-03 study.
Overview of HER2+ Metastatic Colorectal Cancer
Expert oncologists discuss the landscape surrounding HER2+ metastatic CRC, including recommendations for biomarker testing and an overview of scoring criteria.
Patient Profile: A 46-Year-Old Woman With HER2+ Metastatic Colorectal Cancer
A panel of expert oncologists present the case of a 46-year-old woman with HER2+ metastatic colorectal cancer, who is treated with tucatinib in the second-line setting.